Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status

BACKGROUND: Nivolumab has promising efficacy for the treatment of non‐small cell lung cancer (NSCLC). Various predictive factors for nivolumab response in those with NSCLC have been reported, including performance status (PS). The objective of this retrospective study was to determine the predictive...

Descripción completa

Detalles Bibliográficos
Autores principales: Adachi, Yuichi, Tamiya, Akihiro, Taniguchi, Yoshihiko, Enomoto, Takatoshi, Azuma, Kouji, Kouno, Shunichi, Inagaki, Yuji, Saijo, Nobuhiko, Okishio, Kyoichi, Atagi, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013052/
https://www.ncbi.nlm.nih.gov/pubmed/31880861
http://dx.doi.org/10.1002/cam4.2807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013052/
https://www.ncbi.nlm.nih.gov/pubmed/31880861
http://dx.doi.org/10.1002/cam4.2807

Ejemplares similares